Association Between Matrix Metalloproteinase-2 Gene Polymorphism rs243865 and Susceptibility to Cataract Development
NCT ID: NCT05670834
Last Updated: 2024-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
90 participants
OBSERVATIONAL
2023-07-01
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain
NCT02508337
Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
NCT01060072
Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients
NCT00347503
LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT02786901
Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
NCT01230125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The lens undergoes several morphological, biochemical, and physical changes with age which are causal for the formation of age-related cataract.
Oxidative stress can directly influence the solubility of the lens proteins, which increases the lens's opacity.
some studies suggest that inflammatory response may be involved in the occurrence of catarac. and that the pathophysiology is largely attributed to peptide mediators, such as transforming growth factor-beta (TGF-β), epidermal growth factor (EGF) and matrix metalloproteinases (MMPs), with the inhibition of these and other related molecules showing promising results.
Matrix metalloproteinases (MMPs) are a kind of calcium-zinc ion-dependent proteolytic enzyme involved in a variety of cellular processes. MMPs are well known for their ability to degrade the extracellular matrix (ECM) and are involved in several intracellular mechanisms from cell differentiation, proliferation, and angiogenesis to apoptosis.
Several studies' results suggest that the rs243865 (16q13-q21) polymorphism in the promoter region of the metalloproteinase-2 (MMP-2) gene is associated with ophthalmological disorders such as age-related macular degeneration. A recent study suggested that the MMP-2 rs243865 (C/T) polymorphism is associated with an increased risk of cataract.
The expression and activation of MMP-2 can be regulated by environmental influences from surrounding stroma, such as cytokines. some studies suggest that IL6 upregulates the expression of MMPs including MMP-2.
IL-6 is a soluble mediator with a pleiotropic effect on inflammation, immune response, and hematopoiesis. high levels of Il-6 in cataract patients may support the inflammatory response theory of disease development.
this study will follow the tenets of the Declaration of Helsinki. All study participants will sign informed written consent before enrolment in this study.
All study participants will be subjected to complete ophthalmic examination including slit-lamp and fundus examinations. Detailed medical history will be taken.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group (GroupA)
normal healthy non-cataractous volunteers aged ≥21 years
genotyping assay by real-time PCR
genotyping assay of MMP-2 gene with the real-time polymerase chain reaction
ELISA
. IL-6 level in serum will be analyzed by ELISA assay kit.
Group B (experimental group 1)
cataractous patients aged \>50 years and diagnosed with senile cataract.
genotyping assay by real-time PCR
genotyping assay of MMP-2 gene with the real-time polymerase chain reaction
ELISA
. IL-6 level in serum will be analyzed by ELISA assay kit.
Group C (experimental group 2)
cataractous patients aged ≥21 to 50 years and diagnosed with secondary cataract
genotyping assay by real-time PCR
genotyping assay of MMP-2 gene with the real-time polymerase chain reaction
ELISA
. IL-6 level in serum will be analyzed by ELISA assay kit.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
genotyping assay by real-time PCR
genotyping assay of MMP-2 gene with the real-time polymerase chain reaction
ELISA
. IL-6 level in serum will be analyzed by ELISA assay kit.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tasneem Sayed Hawwary Ahmed
demonstrator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine Sohag University
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dong Y, Mu GY, Chen F, Zhao RL, Wang M, Wang B. Correlation between MMP-2 gene polymorphism and cataract susceptibility. Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3167-3172. doi: 10.26355/eurrev_201904_17674.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-22-12-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.